Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT trial of atezolizumab + bevacizumab with TACE strategy for unresectable hepatocellular carcinoma
jRCTs051230037Phase 3Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Overall survival and Conversion rate. Started Aug 2023; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs051230037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230037.